What is the efficacy and safety of zotuximab (Vyloy)?

Zolbetuximab (Vyloy, also known as Zolbetuximab) is an innovative monoclonal antibody drug targeting claudin 18.2 (CLDN18.2). Its outstanding contribution in the treatment of gastric cancer has attracted widespread attention. This drug was specially approved by the Ministry of Health, Labor and Welfare (MHLW) of Japan and is specially designed for patients with CLDN18.2-positive, surgically refractory, advanced or recurrent gastric cancer, bringing them a new hope in treatment.

As the world's first and currently only CLDN18.2 targeted therapy drug, the development and approval process of zotuximab is full of innovations and challenges. It precisely acts on CLDN18.2 on the membrane of cancer cells (such as gastric cancer cells). By tightly binding to this specific antigen, it triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby effectively curbing tumor growth. To ensure the accuracy and effectiveness of treatment, confirmation of CLDN18.2 positivity must be performed by an experienced pathologist or laboratory using approved in vitro diagnostic reagents or medical equipment.

The efficacy and safety of zotuximab have been fully verified in two pivotal phase 3 clinical trials. The SPOTLIGHT study compared zotuximab plus mFOLFOX6 (a chemotherapy regimen containing modified leucovorin, fluorouracil, and oxaliplatin) with placebo plus mFOLFOX6 in the first-line treatment of patients with CLDN18.2-positive, HER2-negative, unresectable or metastatic gastric or gastro-oesophageal nodal cancer. The results showed that the 12-, 18-, and 24-month overall survival rates of the zotuximab group were 67.7%, 50.5%, and 38.8% higher than those of the placebo group, respectively, showing significant advantages compared to 60.0%, 38.1%, and 28.4% of the placebo group.

AnotherGLOW study further explored the efficacy of zotuximab combined with CAPOX (a combination of capecitabine and oxaliplatin) and placebo plus CAPOX in the same patient population. Data show that the overall survival rates of the zotuximab group at 12, 18, and 24 months were 57.5%, 38.1%, and 28.9% respectively, compared with 50.8%, 28.1%, and 17.4% in the placebo group, which also showed obvious treatment advantages. In addition, zotuximab also extended the median overall survival of adult patients with gastric or gastroesophageal cancer by approximately 4 months compared with the placebo group, an outcome that further highlights its important value in actual treatment.

However, like all powerful medications, zotuximab may come with some potential side effects. The most common serious side effects include nausea and vomiting, which may affect more than 1 in 10 patients. Also, be wary of hypersensitivity (allergy) and infusion-related reactions. Other more common side effects include decreased appetite, low albumin levels in the blood (hypoalbuminemia), and swelling of the lower limbs or hands (peripheral edema).

Overall, zotuximab(Vyloy), as an innovative anti-CLDN18.2 monoclonal antibody, has demonstrated excellent efficacy and safety in the treatment of gastric cancer. It not only provides new treatment options for patients with CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer, but also opens up a new path for future cancer treatment research.